This is a multicenter, randomized, Phase 2, double-blind, placebo-controlled study to evaluate the effect of EDG-5506 on the safety, PK, biomarkers, and functional measures in adult and adolescent participants with BMD. This randomized, double-blind, placebo-controlled study will evaluate the safety, pharmacokinetics (PK), and efficacy of EDG-5506 in adults and adolescents …